
Metsera shares surged after Pfizer announced plans to buy the New York biotech in a deal worth up to $7.3 billion, reigniting the obesity drug race.

Metsera shares surged after Pfizer announced plans to buy the New York biotech in a deal worth up to $7.3 billion, reigniting the obesity drug race.